However, downregulation of ECT2, located at 3q26.1 to q26.2, was observed in two patients (Fig. 1). Thus, clinical and histological features were investigated in these patients to examine the association between ECT2 and FSGS. Fig. 1 CGH findings in two patients and another FSGS patient. In the two patients described here, some clustered genes localized in chromosome 3q.26.1–3q.26.2 showed downregulation. Signal indicating the loss of copy number was recognized in the log4 zone, suggesting homozygous deletion of ECT2 in both patients Methods Comparative genomic

hybridization method Array-CGH was used to screen for genes showing up- or downregulation in each subject. We obtained genomic DNA from a reference sample (46,XY) (Promega p/n G1471) and the present patients. CGH was performed using OSI-906 solubility dmso prefabricated oligo-CGH arrays (244-kb arrays; Agilent Technologies, Palo Alto, CA, USA) consisting of about 244,000 in situ-synthesized 60-mer oligonucleotides spanning the entire genome, resulting in an average genomic distance of approximately 12 kb. These probes included both coding and noncoding sequences on every human chromosome. After hybridization had been carried out according to the manufacturer’s instructions, results were visualized using CGHAnalytics 3.4

software (Agilent Technologies). Polymerase chain reaction Genomic DNA was recovered in the aqueous phase and precipitated with ethanol/sodium acetate. The polymerase chain reactions (PCR) were carried out as Fludarabine molecular weight described previously [9]. Specific primers were constructed based on previously published sequence data for human ECT2 coding regions learn more [7]. PCR conditions were as follows: initial denaturation at 94 °C for 5 min, followed by 35 cycles of denaturation at 94 °C for 30 s, annealing

at 63 °C for 30 s, and extension at 72 °C for 4 min. Analysis of ECT2 was performed after we obtained written informed consent from the patients’ parents or guardians. Immunohistochemical staining Anti-ECT2 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Staining for ECT2 protein in renal tissues was carried out using a previously described immunofluorescence method [9]. Patient presentation Patient 1 The patient is a boy who is currently 8 years old. No abnormality had been noted in the perinatal period, and he was born by spontaneous delivery at full term. He is an only child and has no siblings. His parents were unrelated and healthy. No inherited kidney disease or other congenital CP673451 anomalies of the kidney were found in his family members. At 3 years of age, he was brought to our department because of facial edema developing after acute enteritis. No contributory family or past medical history was obtained. On admission, systemic edema and ascites were evident. Mild mental retardation was present (Wisconsin Intelligence Scale for Children or WISC: 70), but motor functions were normal.